Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference
Ocugen, Inc. (OCGN)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, to be held February 17-18, 2020 in Hollywood, Florida. Sanjay Subramanian, Chief Financial Officer of Ocugen, will highlight Ocugen’s ophthalmology pipeline, which includes small molecules, novel biologics and a breakthrough modifier gene therapy platform. Ocugen is currently conducting a Phase 3 clinical trial for OCU300, its small molecule product candidate designed to treat patients with ocular Graft versus Host Disease (oGVHD), with topline results expected in the second half of 2020. Presentation Details:Date: Monday, February 17, 2020Time: 4:30 PM (Eastern Time)Location: Hard Rock Hotel & Casino, Terrace Ballroom D A high-definition vide
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]Yahoo! Finance
- Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]TheStreet.com
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 4/20/26 - Form PRER14A
- 4/17/26 - Form PRE
- 4/14/26 - Form SCHEDULE
- OCGN's page on the SEC website